Brian Leedman

Brian Leedman is an investor relations and capital raising professional in the biotechnology industry with a background in senior marketing roles at Ernst & Young and Westpac Bank. Mr Leedman served for 10 years as the Vice President, Investor Relations for Nasdaq/ASX listed, pSivida Corp. In 2013, he co-founded two new biotechnology companies that have listed on the ASX and is involved in promoting the sector through his role as chairman (WA) of Ausbiotech, the association of biotechnology companies in Australia. Mr Leedman holds a Bachelor of Economics and a Master of Business Administration from the University of Western Australia where he also served for two years as President of the Graduate Management Association. He is the non-executive director of Paynes Find Gold and a board member of the Australia Israel Chamber of Commerce and Heritage Perth. He is an active speaker on the conference circuit and has chaired a number of national investor relations and capital raising conferences in Sydney and Perth.
Bio last updated 15 Jun 2019

Article Timeline

Access to our data for Brian Leedman is only available to paid subscribers with access.

The search engine is Western Australia's most accurate and comprehensive business listings and searchable database.

Brian Leedman is linked to 8 organisations which are included in 2 lists - Technology Companies and Public Companies - Industrial.

To see the data you will need to .

Total Shareholder Return as at 31/05/19

1 year TSR5 year TSR
thWide Open Agriculture
198thResApp Health14%122%
577thTV2U International-44%-20%
617thVDM Group-50%-34%
819thIntiger Group-83%-13%
728 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Source: Morningstar


Co-Founder; Vice President, Corporate Affairs
Year started and most recent title


136th↑ResApp Health$999k
145th↑TV2U International$640k
146th↑Intiger Group$640k
148th↓VDM Group$561k
149th↑Wide Open Agriculture$552k
197 listed industrial companies ranked by revenue.
Source: Morningstar

BNiQ Disclaimer